GleamWall
中文EN

TVGN Tevogen Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1860871 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.3%
TTM EPS YoY23.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-571.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets421.4%
Debt / equity—
Current ratio0.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.43x
Accruals ratio-325.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$11.11M$31.03M
SG&A expense$15.03M$22.53M
Operating income-$26.14M-$53.56M
Interest expense—$184,037
Income tax$4,750$1,750
Net income-$26.28M-$13.73M
EBITDA-$25.95M-$53.40M
EPS (basic)-8.08-3.50
EPS (diluted)-8.08-3.50
Weighted avg. shares (diluted)3.32M2.93M
Banking
Net interest income-$195,618-$184,037
Balance sheet
Cash & equivalents$552,372$1.28M
Current assets$1.54M$2.36M
PP&E, net$170,308$296,442
Total assets$4.38M$3.46M
Current liabilities$7.07M$9.04M
Total liabilities$12.62M$10.14M
Shareholders' equity-$8.23M-$6.67M
Shares outstanding4.02M3.56M
Cash flow statement
Operating cash flow-$12.33M-$12.00M
Capital expenditure$64,439—
Free cash flow-$12.39M—
Investing cash flow-$64,439—
Financing cash flow$11.66M$12.23M
Depreciation & amortization$190,573$162,209
Stock-based compensation$16.22M$40.76M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.